New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 6, 2013
04:55 EDTALNY, ALNY, ALNY, ALNY, ALNY, ALNY, ALNY, MDCO, MDCO, MDCO, MDCO, MDCO, MDCO, MDCO, PRGO, PRGO, PRGO, PRGO, PRGO, PRGO, PRGO, TSRO, TSRO, TSRO, TSRO, TSRO, TSRO, TSRO, MGNX, MGNX, MGNX, MGNX, MGNX, MGNX, MGNX, RGEN, RGEN, RGEN, RGEN, RGEN, RGEN, RGEN, ACT, ACT, ACT, ACT, ACT, ACT, ACT, BMY, BMY, BMY, BMY, BMY, BMY, BMY, ENDP, ENDP, ENDP, ENDP, ENDP, ENDP, ENDP, GSK, GSK, GSK, GSK, GSK, GSK, GSK, MRK, MRK, MRK, MRK, MRK, MRK, MRK, NVS, NVS, NVS, NVS, NVS, NVS, NVS, SHPG, SHPG, SHPG, SHPG, SHPG, SHPG, SHPGFBN Securities to host a bus tour
5th Semi-Annual Silicon Valley Technology Bus Tour visits companies throughout the Silicon Valley on December 6-12.
News For SHPG;NVS;MRK;GSK;ENDP;BMY;ACT;RGEN;MGNX;TSRO;PRGO;MDCO;ALNY From The Last 14 Days
Check below for free stories on SHPG;NVS;MRK;GSK;ENDP;BMY;ACT;RGEN;MGNX;TSRO;PRGO;MDCO;ALNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 9, 2014
07:09 EDTNVS, MRKReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Subscribe for More Information
April 8, 2014
11:03 EDTGSK, BMY, ALNY, MRKPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
09:17 EDTACTActavis recommended on pullback at UBS
Subscribe for More Information
08:46 EDTGSKTeva announces first approval, launch of generic Lovaza capsules in the U.S.
Teva (TEVA) announces the approval of the generic equivalent to Lovaza in the United States. Teva believes it is first-to-file and thus far is the only company to receive an approval from FDA. Teva plans to commence shipping immediately. Lovaza Capsules, marketed by GlaxoSmithKline (GSK), had annual sales of approximately $1.1B in the United States, according to IMS data as of December 2013.
07:22 EDTNVS, GSKCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.
07:08 EDTACTDrug deals increase to new high, Bloomberg says
M&A activity in the specialty pharmaceuticals industry has reached a new high after Mallinckrodt (MNK) recently bought Questcor (QCOR) for $5.6B, reported Bloomberg. Drugmakers from Actavis (ACT) to Valeant (VRX) are widening their suites of drugs through takeovers that immediately increased earnings with the help of lower corporate tax rates in countries such as Ireland. Reference Link
April 7, 2014
14:18 EDTGSKGlaxoSmithKline reports 14.1% stake in Applied Genetic Technologies
Subscribe for More Information
14:09 EDTPRGOSun Pharmaceutical agrees to acquire generic drugmaker Ranbaxy
Subscribe for More Information
09:01 EDTSHPGGenocea names Jonathan Poole as CFO
Subscribe for More Information
08:09 EDTALNY, MRKAlnylam's McSwiggen patent upheld in European opposition proceedings
Subscribe for More Information
08:06 EDTBMYBristol-Myers submits NDAs for Daclatasvir and Asunaprevir to FDA
Subscribe for More Information
07:31 EDTALNYAlnylam shares 'very attractive' at current levels, says Leerink
Subscribe for More Information
07:27 EDTMRK, NVS, TSROAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
05:32 EDTNVSNovartis Bexsero vaccine receives FDA Breakthrough Therapy designation
Novartis announced that Bexsero, Meningococcal Group B Vaccine, has received a Breakthrough Therapy designation from the FDA. Bexsero is already approved in Europe, Canada and Australia to help protect against invasive meningococcal disease caused by serogroup B. Novartis plans to file for U.S. licensure of Bexsero as early as Q2; exact timing will depend on guidance from the FDA. This is the fourth Breakthrough Therapy designation for Novartis, underscoring leadership in developing innovative therapies and vaccines. This announcement comes on the heels of a landmark decision from regulators in the UK, where the Joint Committee on Vaccination and Immunisation recommended the inclusion of Bexsero in the country's National Immunisation Programme for routine use in infants from two months of age.
April 6, 2014
16:31 EDTMGNXMacroGenics presents data demonstrating MGD007 activity in colorectal cancer
Subscribe for More Information
16:23 EDTGSKGlaxoSmithKline investigates bribery allegations in Iraq, WSJ says
GlaxoSmithKline is investigating allegations of bribery by employees in Iraq, says the Wall Street Journal, citing emails reviewed by the publication. Reference Link
13:37 EDTMRKMerck presents findings on clinical outcomes following treatment with MK-3475
Subscribe for More Information
April 4, 2014
08:43 EDTMDCOPointState Capital reports 7.3% passive stake in The Medicines Co.
Subscribe for More Information
08:07 EDTMRKMerck, Ferring announce collaboration with WHO
Merck and Ferring Pharmaceuticals announced their collaboration with the World Health Organization to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding in women after childbirth, that is designed to be stable at room temperature, even in hot and tropical climates. Currently, oxytocin, the standard medicine administered for the prevention of excessive bleeding, is temperature-sensitive and requires sustained cold distribution and storage in hot climates. The WHO will conduct a multi-country clinical study to evaluate the effectiveness of room-temperature-stable carbetocin, as compared to oxytocin. The development of a medicine that can be stored at room temperature has the potential to significantly improve management of bleeding following childbirth in the many areas of the world where cold storage is difficult to achieve and maintain, and thereby help reduce maternal deaths in those areas. Starting this year, the study will take place in 12 countries around the world and enroll approximately 29,000 women. If the results of the study are positive, the organizations will work together with the aim of making the medicine available in developing countries that have a high burden of maternal mortality at an affordable and sustainable public-sector price.
06:29 EDTGSKGlaxoSmithKline cuts China employees amid probe, WSJ reports
According to a source, as it deals with a bribery probe in Beijing, GlaxoSmithKline is cutting employees in China, the Wall Street Journal reports. It is unclear how many of Glaxo's 7,000 employees in China have been let go. Reference Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use